PACT - Public Activities Coordination Tool

PACT - Public Activities Coordination Tool

PACT - Public Activities Coordination Tool

The public activities coordination tool (PACT) provides an overview of the substance-specific activities that authorities are working on under REACH and the CLP Regulation. These activities are being carried out in line with ECHA’s Integrated Regulatory Strategy.

PACT provides up-to-date information on the activities planned, ongoing or completed by ECHA and/or MSCAs for a given substance in the following areas:

  • Data generation and assessment – dossier evaluation, substance evaluation, informal hazard assessment (PBT/vPvB/ED).
  • Assessment of regulatory needs (ARN).
  • Regulatory risk management – harmonised classification and labelling (CLH) , SVHC identification, recommendations for inclusion in the Authorisation List, restriction.

A summary of all the substance-specific activities can be found under ‘Details’ for each entry.

Dapsone

EC / List no: 201-248-4 CAS no: 80-08-0
Data generation and assessment
DEv - Dossier evaluation
DEv 1
Scope
Comprehensive
Status
Concluded
Decision date
Decision
Latest update
26-nov-2022
Additional information
ECHA has stopped the assessment after the registrant(s) submitted new information.
More information View
DEv 2
Scope
Comprehensive
Status
Concluded
Decision date
19-lug-2017
Decision
Latest update
26-nov-2022
Additional information
More information View
SEv - Substance evaluation (Community Rolling Action Plan (CoRAP))
SEv 1
Evaluating Member State
Germany
Co-Evaluating Member State
Initial grounds for concern
Potential endocrine disruptor
Year
2016
Status
Concluded
Conclusion document
Latest update
25-mar-2020
More information View
ED - Endocrine disruptor assessment
ED 1
Authority
Germany
Status
Concluded
Outcome
postponed
Hazard assessment outcome document
Remarks
According to the SEv conclusion the initial ED concern cannot be rejected. There is weak evidence from SAR/QSAR and read across that dapsone binds to the ER and might exert endocrine effects. Data availability is very limited in general, also with respect to in vivo data. Further in vitro and in vivo data would be needed to clarify the concern. Data on BPS from the ongoing substance evaluation could also provide relevant information.

However, evidence for a probable exposure is not sufficient. Dapsone is not detected in the environment (few monitoring studies) and the current uses are all industrial and closed systems, predicted emissions are stated to be extremely low. Also, here data availability was limited.

In total, the evidence for both ED and exposure are too weak to justify data requests. This was discussed in the ED EG and considered that requests to clarify an ED concern would not be justified if there is no indication for a relevant exposure. In particular as only in silico evidence on CF level 1 support an ED concern.
Concern
Endocrine disruption
Date of intention
13-set-2016
Date of hazard assessment
Latest update
05-nov-2021
More information View

List entry date: 14-gen-2016

Export search results to: